Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer
Autore:
Delaloge, S; Laadem, A; Taamma, A; Chouaki, N; Cvitkovic, E; Pautier, P; Misset, JL; Lhomme, C;
Indirizzi:
Inst Gustave Roussy, Dept Gynecol Oncol, F-94800 Villejuif, France Inst Gustave Roussy Villejuif France F-94800 , F-94800 Villejuif, France Hop Paul Brousse, Dept Med Oncol, Villejuif, France Hop Paul Brousse Villejuif France se, Dept Med Oncol, Villejuif, France Cvitkovic & Associes Consultants, Villejuif, France Cvitkovic & Associes Consultants Villejuif France ts, Villejuif, France
Titolo Testata:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
fascicolo: 6, volume: 23, anno: 2000,
pagine: 569 - 574
SICI:
0277-3732(200012)23:6<569:PSOTPO>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; CARCINOMA; TOPOTECAN;
Keywords:
paclitaxel; oxaliplatin; cisplatin; advance ovarian cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Delaloge, S Inst Gustave Roussy, Dept Gynecol Oncol, 39 Rue Camille Desmoulins, F-94800 Villejuif, France Inst Gustave Roussy 39 Rue Camille Desmoulins Villejuif France F-94800
Citazione:
S. Delaloge et al., "Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer", AM J CL ONC, 23(6), 2000, pp. 569-574

Abstract

To determine the feasibility of the paclitaxel, oxaliplatin, cisplatin combination in advanced ovarian cancer (AOC), 15 patients with AOC (8 chemonaive, and 7 second-line, disease-free interval greater than or equal to 12 months) received paclitaxel 135 mg/m(2) at day 1, with oxaliplatin 100 mg/m(2) and cisplatin 75 mg/m(2) at day 2, every 3 weeks for 6 cycles. Pretreatedpatients received prophylactic granulocyte colony-stimulating factor (5 mug/kg/d, days 6-13). Seventy cycles were administered; median 5 (range: 2-6 cycles) in chemonaive, and 4 (range: 2-6) in pretreated patients. There were grades LII to IV neutropenia in 77%, febrile neutropenia in 24%, and grades III to IV thrombocytopenia in 4% of the cycles. Besides neutropenia, cumulative neurosensory toxicity was also limiting although reversible, with National Cancer Institute Common Toxicity Criteria grades II to III observedin 13 patients. Three of the pretreated patients had complete responses (43%), three had partial responses, and one had disease stabilization. Six ofthe 8 chemonaive patients had complete responses (75%), 1 had disease stabilization, and 1 had disease progression. The median follow-up is 17 months(range: 9-20 months) in chemonaive and 41 months (range: 13-58 months) in pretreated patients, and time to progression has been consistently more than 12 months, with 6 patients (5 chemonaive) still progression free (range: 15+ to 22+ months). This active combination shows acceptable hematologic toxicity, and reversible cumulative neurosensory toxicity. Further clinical exploration of the present combination appears warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 08:13:23